Bionomics to Host KOL Webinar on BNC210 and Social Anxiety Disorder

September 21, 2022

https://www.globenewswire.com/news-release/2022/09/21/2519940/0/en/Bionomics-to-Host-KOL-Webinar-on-BNC210-and-Social-Anxiety-Disorder.html

ADELAIDE, Australia, Sept. 21, 2022 (GLOBE NEWSWIRE) — Bionomics Limited (ASX:BNO, Nasdaq:BNOX) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will host a Key Opinion Leader (KOL) webinar on BNC210, a proprietary, first-in-class oral therapeutic with potential to treat Social Anxiety Disorder (SAD) on Wednesday, October 12, 2022 at 2:30pm – 3:30pm ET.

Read more at globenewswire.com

Related news for (BNOX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.